Aimovig Alternatives for Migraine Prevention

Aimovig received FDA approval in 2018 as the first preventive migraine treatment in the CGRP-targeting drug class. It remains one option among a wider range of preventive treatments that now includes other injectable CGRP antibodies, oral CGRP receptor antagonists, infusion therapy, and FDA-cleared neuromodulation devices.

People may explore an Aimovig alternative because of treatment format, side effects, prescription access, insurance requirements, recurring cost, or a preference for a drug-free option. This guide reviews eight alternatives using practical criteria such as indication, administration method, age range, prescription status, treatment schedule, and ongoing access requirements.

Cefaly ranks first because it combines prescription-free access, a reusable at-home design, and both acute and preventive treatment programs in one drug-free device for adults. This ranking reflects accessibility and treatment scope rather than a head-to-head claim that Cefaly is clinically superior to Aimovig or another migraine treatment.

Key Takeaways

• Cefaly provides two treatment programs in one device. It is FDA-cleared for acute treatment of migraine with or without aura and preventive treatment of episodic migraine in adults 18 and older.
• Cefaly does not require a prescription. Its 60-minute Acute program and 20-minute daily Prevent program use external trigeminal nerve stimulation through a forehead electrode.
• Cefaly has sham-controlled clinical evidence. The TEAM study evaluated acute treatment, while PREMICE evaluated episodic migraine prevention. These studies did not compare Cefaly directly with Aimovig.
• Other alternatives use different formats. Options include monthly or quarterly injections, daily or every-other-day tablets, quarterly IV infusions, upper-arm stimulation, neck stimulation, and magnetic pulses delivered at the back of the head.
• Cost comparisons require context. Medication costs depend heavily on insurance and assistance programs, while device costs may involve an initial purchase, refill, electrode, or subscription model.

1. Cefaly

Cefaly is an FDA-cleared, non-invasive, drug-free migraine device that uses external trigeminal nerve stimulation, or e-TNS. A reusable device attaches magnetically to an adhesive electrode positioned on the forehead between and just above the eyebrows. The stimulation targets endings of the trigeminal nerve, a major pathway involved in migraine pain.

Cefaly is available without a prescription in the United States, Canada, the European Union, and other markets. Its combination of prescription-free access and dual treatment programs makes it a particularly practical Aimovig alternative for adults who want to explore migraine neuromodulation without adding another medication to their routine.

Key Features

• Acute treatment: A 60-minute program for acute treatment of migraine with or without aura in adults 18 and older
• Preventive treatment: A 20-minute daily program for preventive treatment of episodic migraine in adults 18 and older
• Reusable design: The device is purchased once, while adhesive electrodes are replaced over time
• Prescription-free access: No prescription is required for eligible adult users
• Health spending: Cefaly is HSA/FSA eligible, subject to individual plan rules
• Tracking support: The Cefaly app supports device control, treatment tracking, migraine logging, reports, and compatible wearable integrations where available
• User support: Free one-on-one coaching is available in supported regions

The Cefaly Migraine Relief app, Cefaly Connected device, and coaching services are not yet available in the European Union.

Cefaly Clinical Evidence

Cefaly’s clinical studies include sham-controlled research for both acute and preventive treatment.

In the TEAM trial, 69.5% of Cefaly-treated participants achieved pain relief at the two-hour assessment, compared with 55.2% using sham treatment. The study evaluated Cefaly against sham, not against Aimovig or another medication.

In the PREMICE trial, 38.1% of participants using Cefaly achieved at least a 50% reduction in monthly migraine days after three months, compared with 12.1% using sham treatment. Acute migraine medication intake decreased 36.6% among all Cefaly-treated participants and 74.4% among preventive-treatment responders.

Safety and Individual Considerations

No serious adverse effects were reported in Cefaly’s clinical studies. Reported side effects are generally minor and reversible after treatment stops. Sleepiness and headache after a session are listed as common; temporary forehead redness and nausea are uncommon; and forehead skin allergy is rare.

Cefaly is contraindicated for people with implanted metallic or electronic devices in the head, a cardiac pacemaker, or an implanted or wearable defibrillator. People who are pregnant, breastfeeding, managing a complex medical history, changing medications, or experiencing new or unusual symptoms should discuss device use with a healthcare provider.

Pricing and Returns

Cefaly currently lists the device price at $509. Replacement electrodes are the primary recurring supply cost. Financing and insurance information are available through Cefaly, and eligible direct purchases are covered by a 90-day return window measured from the product delivery date.

2. Ajovy

Ajovy, or fremanezumab-vfrm, is a prescription monoclonal antibody used for migraine prevention. Unlike Aimovig, which targets the CGRP receptor, Ajovy binds to the CGRP ligand.

Practical Differences

• Ajovy is administered by subcutaneous injection
• Adults can use a 225 mg monthly schedule or a 675 mg quarterly schedule
• The quarterly dose requires three consecutive 225 mg injections
• Autoinjector and prefilled syringe formats are available
• A prescription and pharmacy access are required

Ajovy may be relevant when dosing frequency and injection schedule are central considerations.

3. Emgality

Emgality, or galcanezumab-gnlm, is a prescription CGRP monoclonal antibody administered by subcutaneous injection. It binds to the CGRP ligand rather than the CGRP receptor.

Practical Differences

• Emgality uses a monthly self-injection schedule after an initial loading dose for migraine prevention
• It is available in autoinjector and prefilled syringe formats
• It is also FDA-approved for the treatment of episodic cluster headache in adults
• A prescription and pharmacy access are required

Emgality may be considered when a monthly at-home injection format fits a person’s treatment plan. 

4. Vyepti

Vyepti, or eptinezumab-jjmr, is a prescription CGRP monoclonal antibody administered through intravenous infusion. It is delivered in a healthcare setting rather than self-injected at home.

Practical Differences

• Vyepti is administered every three months
• Treatment requires an IV infusion in a clinic, infusion center, or other qualified setting
• The healthcare setting removes the need for self-injection
• Medication, administration, and facility charges may be billed separately
• A prescription and scheduled clinical visits are required

5. Oral CGRP Options

Oral CGRP receptor antagonists, often called gepants, provide pill-based alternatives to injectable or infused CGRP treatments.

Qulipta

Qulipta, or atogepant, is a prescription tablet used for preventive treatment of migraine in adults.

• It is taken once daily
• Available strengths include 10 mg, 30 mg, and 60 mg
• Dose selection can depend on migraine type, kidney or liver function, and drug interactions
• It is designed for prevention rather than acute treatment

Nurtec ODT

Nurtec ODT, or rimegepant, is a prescription orally disintegrating tablet with both acute and preventive indications in adults.

• It is indicated for acute treatment of migraine with or without aura
• It is also indicated for preventive treatment of episodic migraine
• Preventive dosing is 75 mg every other day
• The tablet dissolves on or under the tongue without requiring water

6. Nerivio

Nerivio is a prescription remote electrical neuromodulation device worn on the upper arm. It is controlled through a smartphone app and is indicated for acute and preventive treatment of migraine with or without aura in people 8 years and older.

Practical Differences

• The device is worn on the upper arm instead of the head or neck
• Each session lasts 45 minutes
• It can be used at the onset of migraine for acute treatment or every other day for prevention
• Smartphone access is required for treatment control
• Current Nerivio devices or refill units provide 18 treatment sessions before a refill is required
• A prescription is required

Nerivio may be relevant when pediatric eligibility or upper-arm placement is an important practical factor. 

7. gammaCore

gammaCore is a handheld prescription device that provides non-invasive vagus nerve stimulation through the side of the neck. It is cleared for acute and preventive migraine treatment in adolescents age 12 and older and adults, with additional cleared indications for certain other headache disorders.

Practical Differences

• The device is applied to the side of the neck
• Treatment is delivered in brief stimulation cycles
• It does not use a forehead electrode, upper-arm band, injection, or infusion
• It requires a prescription
• Coverage and dispensing pathways vary

The device’s neck placement and multiple headache indications distinguish it from forehead-based e-TNS devices. 

8. SAVI Dual

SAVI Dual, formerly associated with the SpringTMS name, uses single-pulse transcranial magnetic stimulation. The device is held against the back of the head and delivers a brief magnetic pulse.

Practical Differences

• SAVI Dual is indicated for acute and preventive treatment of migraine in people 12 years and older
• It is designed for self-treatment in home and other settings
• It uses magnetic stimulation rather than electrical stimulation, injection, tablets, or infusion
• It requires a prescription
• Access commonly involves an ongoing program or subscription arrangement

Cost and Access Considerations

Migraine-treatment costs cannot be compared accurately using a single class-wide number. The amount a person pays can depend on insurance coverage, deductibles, prior authorization, copay assistance, pharmacy or infusion benefits, device refill requirements, and regional availability.

Cefaly uses an ownership model. The device currently costs $509, and replacement electrodes are the main ongoing expense. Eligible buyers may use HSA or FSA funds, financing may be available, and direct purchases have a 90-day satisfaction-return period.

Prescription CGRP medicines can involve pharmacy-benefit rules, prior authorization, and manufacturer assistance programs. Vyepti can also involve infusion and facility charges. Nerivio uses a refill model with a fixed number of treatments per refill, while gammaCore and SAVI Dual access may involve dispensing or subscription arrangements.

For a meaningful comparison, review the total expected cost over the intended treatment period rather than comparing only an advertised first-month price or a medication’s list price.

How the Alternatives Differ

The most useful comparison is not simply medication versus device. Each option has a different combination of treatment purpose, access, placement, schedule, and recurring requirements.

Cefaly

Among the options covered here, Cefaly uniquely combines all of the following practical features:

• Prescription-free U.S., Canada, and EU access
• A reusable at-home device
• Acute and preventive programs in one unit
• Forehead-based e-TNS
• A 20-minute daily preventive program
• A 60-minute acute program
• Cefaly-specific sham-controlled evidence for both treatment purposes

Other CGRP Antibodies

Ajovy and Emgality are self-injected at home, while Vyepti is infused every three months in a healthcare setting. All require prescriptions and may involve insurer authorization.

Oral CGRP Options

Qulipta offers once-daily preventive dosing. Nurtec ODT offers both acute and preventive indications in an orally dissolving format.

Other Neuromodulation Devices

Nerivio uses upper-arm stimulation and an app. gammaCore stimulates the vagus nerve at the neck. SAVI Dual delivers magnetic pulses at the back of the head. All three require prescriptions.

Why Cefaly Ranks First

Cefaly is the strongest overall fit in this guide for adults prioritizing drug-free access, treatment flexibility, and at-home reuse. Its main advantages are practical and verifiable:

• It is available without a prescription
• It includes both acute and preventive treatment programs
• It is reusable rather than limited to a set number of total treatments
• It does not add a medication to the treatment routine
• Its support ecosystem includes app-based tracking and coaching, where available
• Eligible direct purchases include a 90-day satisfaction-return period

Cefaly does not cure migraine, permanently eliminate attacks, or guarantee results. Individual response varies, and no Cefaly study cited here directly compared the device with Aimovig.

Frequently Asked Questions

What is the main difference between Cefaly and Aimovig?

Cefaly is a non-invasive medical device that uses e-TNS through a forehead electrode. It is available without a prescription and includes a 60-minute Acute program and a 20-minute daily Prevent program. Aimovig is a prescription monoclonal antibody that blocks the CGRP receptor and is administered by monthly subcutaneous injection.

What does clinical research show about Cefaly?

Cefaly has been evaluated against sham treatment in separate acute and preventive studies. In the TEAM trial, 69.5% of Cefaly-treated participants achieved pain relief at the two-hour assessment, compared with 55.2% using sham. In PREMICE, 38.1% achieved at least a 50% reduction in monthly migraine days after three months, compared with 12.1% using sham. These studies did not compare Cefaly directly with Aimovig.

Can Cefaly be used with migraine medication?

Cefaly is drug-free and does not have pharmacologic drug interactions. It may be incorporated alongside medication in an individualized migraine plan. Medication should not be stopped, started, or changed without guidance from a qualified healthcare provider.

Is Cefaly covered by insurance?

Coverage varies by plan. Cefaly provides coverage resources, and the device and electrodes are HSA/FSA eligible subject to plan rules. Eligible purchases made directly through the official website may be returned within 90 calendar days of delivery under the current return policy.

Is Cefaly appropriate during pregnancy or breastfeeding?

Cefaly is drug-free, but its safety and effectiveness have not been fully established for every pregnant or breastfeeding individual. A healthcare provider should evaluate whether Cefaly is appropriate based on the person’s health history and current treatment plan.

How can someone compare these alternatives with a provider?

Useful comparison points include whether the goal is acute treatment, prevention, or both; prescription status; age indication; treatment placement; session or dosing schedule; recurring supply requirements; insurance rules; contraindications; and the person’s broader medical history. Cefaly also maintains a directory of certified providers for people seeking device-specific clinical support.